Modified virus vectors and methods of making and using the same
View Patent ↗The present invention provides AAV capsid proteins (VP1, VP2 and/or VP3) comprising a modification in the amino acid sequence in the three-fold axis loop 4 and virus capsids and virus vectors comprising the modified AAV capsid protein. In particular embodiments, the modification comprises a substitution of one or more amino acids at amino acid positions 585 to 590 (inclusive) of the native AAV2 capsid protein sequence or the corresponding positions of other AAV capsid proteins. The invention also provides methods of administering the virus vectors and virus capsids of the invention to a cell or to a subject in vivo.
1. An adeno-associated virus (AAV) capsid protein, wherein the capsid protein comprises a modification resulting in the amino acid sequence SAQAQA (SEQ ID NO:10) at the amino acids corresponding to amino acid positions 585-590 (VP1 numbering) of the native AAV2 capsid protein.
2. An AAV capsid comprising the AAV capsid protein of claim 1 .
3. A virus vector comprising:
(a) the AAV capsid of claim 2 ; and
(b) a nucleic acid comprising at least one terminal repeat sequence, wherein the nucleic acid is encapsidated by the AAV capsid.
4. A pharmaceutical formulation comprising the virus vector of claim 3 in a pharmaceutically acceptable carrier.
5. An adeno-associated virus (AAV) capsid protein, wherein the capsid protein comprises a modification resulting in the amino acid sequence QANTGP (SEQ ID NO:11) at the amino acids corresponding to amino acid positions 585-590 (VP1 numbering) of the native AAV2 capsid protein.
6. An AAV capsid comprising the AAV capsid protein of claim 5 .
7. A virus vector comprising:
(a) the AAV capsid of claim 6 ; and
(b) a nucleic acid comprising at least one terminal repeat sequence, wherein the nucleic acid is encapsidated by the AAV capsid.
8. A pharmaceutical formulation comprising the virus vector of claim 7 in a pharmaceutically acceptable carrier.